Latest Articles & Resources FEATURED Samsung Biologics Reports KRW 4,557 Billion (USD 3.5 billion) Revenue for FY 2025 Read More » Samsung Biologics Reports KRW 4,557 Billion (USD 3.5 billion) Revenue for FY 2025 Read More » LATEST NEWS + INTERVIEWS Charles River Partners with Gazi University on Gene Therapy CDMO Collaboration Vetter Earns EcoVadis Platinum Rating and SBTi Validation for Emissions Targets Oxford-Harrington Rare Disease Centre – $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Genezen Enters Strategic Manufacturing Partnership with Atsena for AAV Gene Therapy Programmes ten23 health® and BD Partner to Support Supply Chain Readiness for BD Libertas™ Genentech Doubles North Carolina Manufacturing Investment to $2bn Rentschler Biopharma Announces CEO Transition Alcami Corporation Acquires 37,000 sq ft Durham Facility to Grow RTP Presence HRV Global Life Sciences Partners with Haleos Labs on Orphan API Development and Manufacturing Syngene International Extends Bristol Myers Squibb Collaboration Through 2035 Sharp Invests Over €20M to Expand Injectable Packaging Capacity in Europe Onyx Scientific Expands Solid Form Screening Capabilities to Support Complex Molecules China’s Biotech Ascent Reshapes Global Pharma Strategy, Dominates JPM26 Discussions State of Cell & Gene Therapy 2026: Cautious Optimism as Investment Rises Novo Nordisk CEO: We Were ‘Cursed as a Leader’ as Lilly Closes GLP-1 Gap FDA Veteran Pazdur Warns Industry Cites ‘Chaos’ at JPM Healthcare Conference 2026 AGC Biologics Supports Commercial Manufacturing of Waskyra Gene Therapy Following FDA and EU Approvals The New Manufacturing Reality for 2026: The Rise of Radiopharma, Industrialization, and Investment Pressure CDMOs in Radiopharma: Why Legacy Systems Threaten Scale-Up Radiopharmaceutical manufacturing: Why headline capacity breaks down under half-life constraints Radiopharmaceutical Winners Must Compete on Service Excellence – Not Clinical Data PODCAST INTERVIEWS Radiopharmaceutical Winners Must Compete on Service Excellence – Not Clinical Data Simtra BioPharma Solutions CEO Franco Negron on Building Supply Chain Resilience Through Geographic Redundancy How Integrated Drug Development and Manufacturing Creates Speed Advantage in Contract Pharma
Oxford-Harrington Rare Disease Centre – $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034
AGC Biologics Supports Commercial Manufacturing of Waskyra Gene Therapy Following FDA and EU Approvals
The New Manufacturing Reality for 2026: The Rise of Radiopharma, Industrialization, and Investment Pressure
Simtra BioPharma Solutions CEO Franco Negron on Building Supply Chain Resilience Through Geographic Redundancy
